

Anne Åvrehus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3638065/publications.pdf>

Version: 2024-02-01

25
papers

528
citations

932766

10
h-index

752256

20
g-index

25
all docs

25
docs citations

25
times ranked

1084
citing authors

#	ARTICLE	IF	CITATIONS
1	Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirinâ€”A Randomized Controlled Clinical Trial. <i>Viruses</i> , 2022, 14, 614.	1.5	1
2	A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project. <i>BMC Infectious Diseases</i> , 2022, 22, 202.	1.3	5
3	Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1126-1133.	2.8	30
4	Low mortality of hospitalised patients with COVID-19 in a tertiary Danish hospital setting. <i>International Journal of Infectious Diseases</i> , 2021, 102, 212-219.	1.5	6
5	Comparison of six commercially available SARS-CoV-2 antibody assaysâ€”Choice of assay depends on intended use. <i>International Journal of Infectious Diseases</i> , 2021, 103, 381-388.	1.5	34
6	Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101564.	0.7	11
7	Inferior cure rate in pilot study of 4â€”week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. <i>Liver International</i> , 2021, 41, 2601-2610.	1.9	9
8	Emergency department testing is feasible but ineffective to eliminate hepatitis C in Denmark. <i>Infectious Diseases</i> , 2021, 53, 930-941.	1.4	5
9	Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment. <i>Microbiology Resource Announcements</i> , 2021, 10, e0075521.	0.3	2
10	The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (Tâ€™Nâ€™T HepC). <i>BMJ Open</i> , 2020, 10, 039724.	0.8	13
11	Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. <i>PLoS ONE</i> , 2020, 15, e0238203.	1.1	20
12	Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
13	Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
14	Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
15	Hepatitis C prevalence in Denmark in 2016â€”An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
16	How can we achieve WHO's elimination target for hepatitis C incidence?. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 415-417.	3.7	0
17	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019, 39, 20-30.	1.9	88
18	Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registryâ€”based cohort study. <i>Addiction</i> , 2019, 114, 494-503.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018, 68, 402-411.	1.8	105
20	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	3.7	128
21	Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial. <i>Journal of Hepatology</i> , 2018, 68, 840-842.	1.8	19
22	HCV treatment for people with recent drug use: time for new measures of success?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 731-732.	3.7	1
23	Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx257.	0.4	9
24	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections – A Scandinavian real-life study. <i>PLoS ONE</i> , 2017, 12, e0179764.	1.1	28
25	Schistosomiasis-induced squamous cell bladder carcinoma in an HIV-infected patient. <i>International Journal of Infectious Diseases</i> , 2015, 40, 113-115.	1.5	4